
Sign up to save your podcasts
Or


What did UEG Week 2026 offer nurses and allied health professionals? Mary Phillips, pancreatic dietitian and advanced clinical practitioner at a UK tertiary pancreatic centre, asks Deepa Gandhi, endoscopy nurse lead and President of ESGENA, for her highlights from Barcelona. Both keep returning to the human side of care: what complications mean for patients and clinicians, and how to train, support and keep specialist nursing staff.
They discuss the second victim phenomenon, a nurse-led analysis of where time is lost in the endoscopy unit, and bile duct injury after laparoscopic cholecystectomy, a procedure patients tend to see as minor and are less prepared for when it goes wrong. Deepa's abstract highlights include a remote, postal small bowel capsule endoscopy service in Ireland, an activity-based assessment of endoscopy nursing workload and staffing, and advanced nurse practice in Austria. They also cover clinical educators in endoscopy, how nurses assess disease burden in Crohn's disease, long-term follow-up after acute pancreatitis, with its risk of diabetes and, after idiopathic pancreatitis, of cancer, and a multidisciplinary case of refeeding syndrome in anorexia nervosa. The conversation closes on burnout, and Deepa's call for more congress sessions on nurse wellbeing.
Research and further readingDiscussed in the episode (UEG Week 2026 presentations, recordings on Gutflix):
Additional context (not discussed in the episode):
On the final day of UEG Week 2026 in Barcelona, Egle Dieninyte talks to interventional EUS specialist Giuseppe Vanella (Milan) about the endoscopy research that stood out. Several of the strongest studies asked deliberately simple clinical questions.
Key discussion points
Former UEG President Paul Fockens is back from 2 years in New Zealand. He reminisces on teaching, leadership and why nurses it's crucial to keep nurses on side.
in this first part, Eglė talks with Dr Pilar Acedo Nuñez, a senior research fellow and junior principal investigator at UCL. Pilar co-leads the Pereira/Acedo Lab, which works on biomarkers for the early detection of pancreatic cancer and cholangiocarcinoma, and she is a former chair of the UEG Young Talent Group.
Further reading
Ten years after Rome IV, the Rome Foundation published Rome V in 2026, and with it a substantial revision of how disorders of gut–brain interaction (DGBI) are defined, diagnosed and managed. Pradeep Mundre is joined by Maura Corsetti, Associate Professor of Gastroenterology at the University of Nottingham, co-chair of the Rome V Bowel Disorders Committee and a member of the Rome Foundation Board of Directors, to work through what has actually changed, and what survives contact with a busy clinic..
Further reading
Rome Foundation Brain–Gut Axis pocket card — the card Corsetti uses to explain the diagnosis; free download after registration.
Disorders of Gut–Brain Interaction and the Rome V Process — Drossman, Chang & Tack, Gastroenterology 2026;170:1083–98. The Rome V overview: nomenclature, the split between research and clinical criteria, and the rationale for each new diagnosis.
Bowel Disorders — Corsetti, Shin, Lacy et al., Gastroenterology 2026;170:1261–82. Corsetti's own Rome V chapter, containing the revised IBS criteria discussed at length.
Centrally Mediated Disorders of Gastrointestinal Pain — Fukudo, Aziz, Drossman et al., Gastroenterology 2026;170:1283–302. Where adult abdominal migraine (D2) and narcotic bowel syndrome sit in Rome V.
Anorectal Disorders — Rao, Bharucha, Carrington et al., Gastroenterology 2026;170:1318–46. The new anorectal sensory dysfunction disorders and their assessment and treatment.
Rome Foundation Clinical Diagnostic Criteria for Disorders of Gut-Brain Interaction — Gastroenterology 2022;162:675–9. The precursor to the Rome V clinical criteria, developed with primary care input.
The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders — Aziz, Palsson, Törnblom et al., Am J Gastroenterol 2018;113:86–96. The three-country population study underlying the overlap and quality-of-life data.
Rome V: a global framework for disorders of gut–brain interaction — Rome Foundation. Where to find the Rome V products and criteria.
Asked to choose between a flare and a JAK inhibitor in the third trimester, Mette Julsgaard answers in two words: active disease.
Part two picks up where aspirin for preeclampsia ended and moves to the situations that actually keep clinicians awake. Mette Julsgaard, Associate Professor at Aarhus University Hospital and a co-author of the 2025 global consensus statement on pregnancy in IBD, takes Pradeep Mundre through starting upadacitinib at 28 weeks when nothing else was left, why thiopurines should never be initiated in pregnancy even though they can be continued, and how to manage acute severe ulcerative colitis without letting surgery drift.
Also here: why active perianal disease and a pouch push you towards caesarean section and why BCG waits six months but rotavirus does not.
Part one covers fertility, preconception and the full drug run-through, be sure to listen to it, before you start with this episode.
Further reading:
One in three women with IBD believe every IBD drug is harmful in pregnancy. The cost of that belief shows up as flares, preterm births and babies born small for gestational age.
Mette Julsgaard, Associate Professor at Aarhus University Hospital and Director of Denmark's National Centre for Preconception and Pregnancy in Autoimmune Diseases, was a co-author of the 2025 global consensus statement on pregnancy in IBD. With Pradeep Mundre she works through the period before conception: what active disease does to fertility in men and women, what to check at the preconception visit beyond disease activity, and why the stop list is short (JAK inhibitors, S1P receptor modulators and, in women, methotrexate).
Then a drug by drug run through of pregnancy and breastfeeding, including why the biologics reach breast milk at under 1 % of maternal blood levels, as well as the recommendation for the use of aspirin for patients with IBD during pregnancy.
Part two covers flares, surgery, delivery and vaccination and will be published on the 2nd of September 2026.
Further reading:
The literature said 41 to 46% of high-risk early oesophageal cancers already have nodal disease. Newer data from patients followed after endoscopic resection puts it nearer 16%, which means sending all of them to surgery operates on more than 80% for nothing.
Recorded after the UEG online course on oesophageal cancer, three specialists work through the questions the guidelines have not settled. Roos Pouw on when strict endoscopic follow-up can replace oesophagectomy, and exactly what that follow-up schedule looks like. Ana-Maria Bucalau on why six biopsies no longer covers the biomarker panel, and what ESOPEC and MATTERHORN change about neoadjuvant choice. Jessie Elliott on Siewert type II surgery, and on ENSURE, which found intensive surveillance detects recurrence earlier without improving survival while increasing cancer worry.
The SARONG surveillance trials are still recruiting and Jessie is open to hearing from interested centres. Full course at gutflix.eu.
Further reading:
1. ESGE tissue sampling guideline, Part 1 (biopsy numbers)
UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!
In this episode of the UEG Talks conversation between Maria Vehreschild and Pradeep Mundre, we delve into the complexities of the faecal microbiome and the role of faecal microbiota transplantation (FMT) in treating various diseases, particularly C. difficile infections and inflammatory bowel disease (IBD). The discussion covers the historical context of FMT, its mechanisms of action, current treatment guidelines, safety considerations, and the various delivery methods. The conversation also emphasises the need for further research and the importance of professional standards in FMT practices.
UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!
Functional gastrointestinal disorders, or disorder of gut-brain interaction, can be frightening to many GIs. How do I talk to the patient? What can I tell them if there is no improvement in their symptoms? How can I even explain to them what their diagnosis is, if I don’t even know it?
The content of UEG Talks is for healthcare professionals and is purely educational. The views of the speakers are their own and do not necessarily reflect those of United European Gastroenterology. This podcast is not medical advice and should not replace clinical judgment. Always consult official guidelines and relevant experts before making patient care decisions.
From the publisher's feed

10 Listeners